ID   RET_HUMAN               Reviewed;        1114 AA.
AC   P07949; A8K6Z2; Q15250; Q9BTB0; Q9H4A2;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 3.
DT   12-OCT-2022, entry version 268.
DE   RecName: Full=Proto-oncogene tyrosine-protein kinase receptor Ret {ECO:0000305};
DE            EC=2.7.10.1;
DE   AltName: Full=Cadherin family member 12;
DE   AltName: Full=Proto-oncogene c-Ret;
DE   Contains:
DE     RecName: Full=Soluble RET kinase fragment;
DE   Contains:
DE     RecName: Full=Extracellular cell-membrane anchored RET cadherin 120 kDa fragment;
DE   Flags: Precursor;
GN   Name=RET {ECO:0000312|HGNC:HGNC:9967};
GN   Synonyms=CDHF12, CDHR16, PTC, RET51;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT CYS-982.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-280 (ISOFORMS 1/2).
RX   PubMed=2660074;
RA   Takahashi M.;
RT   "Isolation of ret proto-oncogene cDNA with an amino-terminal signal
RT   sequence.";
RL   Oncogene 4:805-806(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114 (ISOFORM 1).
RX   PubMed=3078962;
RA   Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.;
RT   "Cloning and expression of the ret proto-oncogene encoding a tyrosine
RT   kinase with two potential transmembrane domains.";
RL   Oncogene 3:571-578(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063 (ISOFORM 2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH TRIM27.
RX   PubMed=3037315; DOI=10.1128/mcb.7.4.1378-1385.1987;
RA   Takahashi M., Cooper G.M.;
RT   "ret transforming gene encodes a fusion protein homologous to tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 7:1378-1385(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH GOLGA5.
RC   TISSUE=Fibroblast;
RX   PubMed=2734021;
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RT   "Activation of the ret-II oncogene without a sequence encoding a
RT   transmembrane domain and transforming activity of two ret-II oncogene
RT   products differing in carboxy-termini due to alternative splicing.";
RL   Oncogene 4:789-794(1989).
RN   [8]
RP   ERRATUM OF PUBMED:2734021.
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RL   Oncogene 4:1415-1415(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH CCDC6.
RC   TISSUE=Thyroid papillary carcinoma;
RX   PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3;
RA   Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R.,
RA   Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.;
RT   "PTC is a novel rearranged form of the ret proto-oncogene and is frequently
RT   detected in vivo in human thyroid papillary carcinomas.";
RL   Cell 60:557-563(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-770 (ISOFORMS 1/2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH PCM1.
RX   PubMed=10980597; DOI=10.1038/sj.onc.1203772;
RA   Corvi R., Berger N., Balczon R., Romeo G.;
RT   "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.";
RL   Oncogene 19:4236-4242(2000).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TRIM24.
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused to the
RT   RET receptor tyrosine kinase in childhood papillary thyroid carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [12]
RP   PHOSPHORYLATION AT TYR-1015 AND TYR-1062.
RX   PubMed=11061555; DOI=10.1210/jcem.85.10.6882;
RA   Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G.,
RA   Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.;
RT   "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and
RT   ret-derived oncoproteins.";
RL   J. Clin. Endocrinol. Metab. 85:3898-3907(2000).
RN   [13]
RP   PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981; TYR-1015;
RP   TYR-1062; TYR-1090 AND TYR-1096.
RX   PubMed=14711813; DOI=10.1074/jbc.m312600200;
RA   Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R., Kato M.,
RA   Suzuki H., Takahashi M., Nakashima I.;
RT   "Identification of RET autophosphorylation sites by mass spectrometry.";
RL   J. Biol. Chem. 279:14213-14224(2004).
RN   [14]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM27.
RX   PubMed=12787916; DOI=10.1016/s0027-5107(03)00056-3;
RA   Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A., Lushnikov E.,
RA   Roumiantsev P., Matsumoto N., Nakashima M., Meirmanov S., Ohtsuru A.,
RA   Namba H., Tsyb A., Yamashita S.;
RT   "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid
RT   carcinoma from externally irradiated patient.";
RL   Mutat. Res. 527:81-90(2003).
RN   [15]
RP   RETRACTED PAPER.
RX   PubMed=16778204; DOI=10.1158/0008-5472.can-06-0228;
RA   Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M.,
RA   Carlomagno F., Santoro M., Fusco A.;
RT   "The receptor-type protein tyrosine phosphatase J antagonizes the
RT   biochemical and biological effects of RET-derived oncoproteins.";
RL   Cancer Res. 66:6280-6287(2006).
RN   [16]
RP   RETRACTION NOTICE OF PUBMED:16778204.
RX   PubMed=30552125; DOI=10.1158/0008-5472.can-18-3456;
RA   Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M.,
RA   Carlomagno F., Santoro M., Fusco A.;
RL   Cancer Res. 78:6907-6907(2018).
RN   [17]
RP   ACTIVITY REGULATION.
RX   PubMed=17884497; DOI=10.1016/j.bmcl.2007.07.104;
RA   Graham Robinett R., Freemerman A.J., Skinner M.A., Shewchuk L., Lackey K.;
RT   "The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET
RT   kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:5886-5893(2007).
RN   [18]
RP   ACTIVITY REGULATION BY SORAFENIB.
RX   PubMed=17664273; DOI=10.1074/jbc.m703461200;
RA   Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I.,
RA   Links T.P., Hofstra R.M.W., Barford D., Isacke C.M.;
RT   "Sorafenib functions to potently suppress RET tyrosine kinase activity by
RT   direct enzymatic inhibition and promoting RET lysosomal degradation
RT   independent of proteasomal targeting.";
RL   J. Biol. Chem. 282:29230-29240(2007).
RN   [19]
RP   ACTIVITY REGULATION BY 3- AND 4-SUBSTITUTED BETA-CARBOLIN-1-ONES.
RX   PubMed=19053769; DOI=10.1021/jm8007823;
RA   Cincinelli R., Cassinelli G., Dallavalle S., Lanzi C., Merlini L.,
RA   Botta M., Tuccinardi T., Martinelli A., Penco S., Zunino F.;
RT   "Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and
RT   4-substituted beta-carbolin-1-ones.";
RL   J. Med. Chem. 51:7777-7787(2008).
RN   [20]
RP   INTERACTION WITH CD2AP, AND MUTAGENESIS OF LYS-758.
RX   PubMed=18753381; DOI=10.1523/jneurosci.2738-08.2008;
RA   Tsui C.C., Pierchala B.A.;
RT   "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation
RT   of ret signal transduction.";
RL   J. Neurosci. 28:8789-8800(2008).
RN   [21]
RP   INTERACTION WITH AIP.
RX   PubMed=19366855; DOI=10.1210/jc.2008-1980;
RA   Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R., Morra I.,
RA   Melcarne A., Rimondini R., Romeo G., Bonora E.;
RT   "The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon
RT   receptor-interacting protein to alter survivin availability.";
RL   J. Clin. Endocrinol. Metab. 94:2571-2578(2009).
RN   [22]
RP   INDUCTION BY NKX2-1; PHOX2B; SOX10 AND PAX3.
RX   PubMed=19853745; DOI=10.1016/j.jpedsurg.2008.11.055;
RA   Leon T.Y.Y., Ngan E.S.W., Poon H.-C., So M.-T., Lui V.C.H., Tam P.K.H.,
RA   Garcia-Barcelo M.M.;
RT   "Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3.";
RL   J. Pediatr. Surg. 44:1904-1912(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [24]
RP   FUNCTION IN DEVELOPMENT OF MECHANORECEPTORS.
RX   PubMed=20064382; DOI=10.1016/j.neuron.2009.12.014;
RA   Ma Q.;
RT   "RETouching upon mechanoreceptors.";
RL   Neuron 64:773-776(2009).
RN   [25]
RP   ACTIVITY REGULATION, AND REVIEW ON KINASE INHIBITORS.
RX   PubMed=20605972; DOI=10.1210/er.2009-0031;
RA   Ye L., Santarpia L., Gagel R.F.;
RT   "The evolving field of tyrosine kinase inhibitors in the treatment of
RT   endocrine tumors.";
RL   Endocr. Rev. 31:578-599(2010).
RN   [26]
RP   ACTIVITY REGULATION.
RX   PubMed=20409618; DOI=10.1016/j.ejmech.2010.03.017;
RA   Brandt W., Mologni L., Preu L., Lemcke T., Gambacorti-Passerini C.,
RA   Kunick C.;
RT   "Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-
RT   thienyl)nicotinonitrile scaffold.";
RL   Eur. J. Med. Chem. 45:2919-2927(2010).
RN   [27]
RP   FUNCTION IN PITUITARY.
RX   PubMed=20616503; DOI=10.1159/000318502;
RA   Garcia-Lavandeira M., Diaz-Rodriguez E., Garcia-Rendueles M.E.,
RA   Rodrigues J.S., Perez-Romero S., Bravo S.B., Alvarez C.V.;
RT   "Functional role of the RET dependence receptor, GFRa co-receptors and
RT   ligands in the pituitary.";
RL   Front. Horm. Res. 38:127-138(2010).
RN   [28]
RP   FUNCTION IN CELL ADHESION/MIGRATION.
RX   PubMed=20702524; DOI=10.1210/jc.2010-0771;
RA   Cockburn J.G., Richardson D.S., Gujral T.S., Mulligan L.M.;
RT   "RET-mediated cell adhesion and migration require multiple integrin
RT   subunits.";
RL   J. Clin. Endocrinol. Metab. 95:E342-E346(2010).
RN   [29]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19823924; DOI=10.1007/s10895-009-0548-x;
RA   Richardson D.S., Mulligan L.M.;
RT   "Direct visualization of vesicle maturation and plasma membrane protein
RT   trafficking.";
RL   J. Fluoresc. 20:401-405(2010).
RN   [30]
RP   ACTIVITY REGULATION.
RX   PubMed=21134556; DOI=10.1016/j.surg.2010.09.026;
RA   Samadi A.K., Mukerji R., Shah A., Timmermann B.N., Cohen M.S.;
RT   "A novel RET inhibitor with potent efficacy against medullary thyroid
RT   cancer in vivo.";
RL   Surgery 148:1228-1236(2010).
RN   [31]
RP   FUNCTION IN CELL ADHESION, FUNCTION IN APOPTOSIS, PROTEOLYTIC PROCESSING BY
RP   CASPASE-3 AT ASP-707 AND ASP-1017, MUTAGENESIS OF ASP-707; LYS-758 AND
RP   708-ALA--SER-1114, AND SUBUNIT.
RX   PubMed=21357690; DOI=10.1074/jbc.m110.195461;
RA   Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P.;
RT   "RET modulates cell adhesion via its cleavage by caspase in sympathetic
RT   neurons.";
RL   J. Biol. Chem. 286:14628-14638(2011).
RN   [32]
RP   INTERACTION WITH PTK2/FAK1, AND FUNCTION IN PTK2/FAK1 PHOSPHORYLATION.
RX   PubMed=21454698; DOI=10.1074/jbc.m110.168500;
RA   Plaza-Menacho I., Morandi A., Mologni L., Boender P.,
RA   Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P.,
RA   McDonald N.Q., Isacke C.M.;
RT   "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming
RT   a direct and reciprocal RET-FAK transactivation mechanism.";
RL   J. Biol. Chem. 286:17292-17302(2011).
RN   [33]
RP   INTERACTION WITH GDNF, AND SUBCELLULAR LOCATION.
RX   PubMed=21994944; DOI=10.1074/jbc.m111.246413;
RA   Geng Z., Xu F.Y., Huang S.H., Chen Z.Y.;
RT   "Sorting protein-related receptor SorLA controls regulated secretion of
RT   glial cell line-derived neurotrophic factor.";
RL   J. Biol. Chem. 286:41871-41882(2011).
RN   [34]
RP   INTERACTION WITH GFRA1, AND SUBCELLULAR LOCATION.
RX   PubMed=23333276; DOI=10.1016/j.celrep.2012.12.011;
RA   Glerup S., Lume M., Olsen D., Nyengaard J.R., Vaegter C.B., Gustafsen C.,
RA   Christensen E.I., Kjolby M., Hay-Schmidt A., Bender D., Madsen P.,
RA   Saarma M., Nykjaer A., Petersen C.M.;
RT   "SorLA controls neurotrophic activity by sorting of GDNF and its receptors
RT   GFRalpha1 and RET.";
RL   Cell Rep. 3:186-199(2013).
RN   [35]
RP   INTERACTION WITH GFRAL, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF
RP   TYR-1062.
RX   PubMed=28953886; DOI=10.1038/nature24042;
RA   Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J.,
RA   Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A.,
RA   Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M.,
RA   Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H.,
RA   Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y.,
RA   Tian H., Allan B.B.;
RT   "Non-homeostatic body weight regulation through a brainstem-restricted
RT   receptor for GDF15.";
RL   Nature 550:255-259(2017).
RN   [36]
RP   ERRATUM OF PUBMED:28953886.
RX   PubMed=29144449; DOI=10.1038/nature24481;
RA   Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J.,
RA   Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A.,
RA   Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M.,
RA   Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H.,
RA   Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y.,
RA   Tian H., Allan B.B.;
RT   "Non-homeostatic body weight regulation through a brainstem-restricted
RT   receptor for GDF15.";
RL   Nature 551:398-398(2017).
RN   [37]
RP   FUNCTION, AND INTERACTION WITH GFRAL.
RX   PubMed=28846097; DOI=10.1038/nm.4392;
RA   Mullican S.E., Lin-Schmidt X., Chin C.N., Chavez J.A., Furman J.L.,
RA   Armstrong A.A., Beck S.C., South V.J., Dinh T.Q., Cash-Mason T.D.,
RA   Cavanaugh C.R., Nelson S., Huang C., Hunter M.J., Rangwala S.M.;
RT   "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in
RT   mice and nonhuman primates.";
RL   Nat. Med. 23:1150-1157(2017).
RN   [38]
RP   FUNCTION, INTERACTION WITH GFRAL, AND PHOSPHORYLATION AT TYR-905 AND
RP   TYR-1062.
RX   PubMed=28846099; DOI=10.1038/nm.4394;
RA   Yang L., Chang C.C., Sun Z., Madsen D., Zhu H., Padkjaer S.B., Wu X.,
RA   Huang T., Hultman K., Paulsen S.J., Wang J., Bugge A., Frantzen J.B.,
RA   Noergaard P., Jeppesen J.F., Yang Z., Secher A., Chen H., Li X., John L.M.,
RA   Shan B., He Z., Gao X., Su J., Hansen K.T., Yang W., Joergensen S.B.;
RT   "GFRAL is the receptor for GDF15 and is required for the anti-obesity
RT   effects of the ligand.";
RL   Nat. Med. 23:1158-1166(2017).
RN   [39] {ECO:0007744|PDB:2IVS, ECO:0007744|PDB:2IVT, ECO:0007744|PDB:2IVU, ECO:0007744|PDB:2IVV}
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX WITH
RP   INHIBITORS, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION AT
RP   TYR-900 AND TYR-905.
RX   PubMed=16928683; DOI=10.1074/jbc.m605604200;
RA   Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S.,
RA   Santoro M., Ibanez C.F., McDonald N.Q.;
RT   "Structure and chemical inhibition of the RET tyrosine kinase domain.";
RL   J. Biol. Chem. 281:33577-33587(2006).
RN   [40] {ECO:0007744|PDB:2X2K, ECO:0007744|PDB:2X2L, ECO:0007744|PDB:2X2M}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 705-1013 IN COMPLEX WITH
RP   INHIBITORS, ACTIVITY REGULATION, AND PHOSPHORYLATION AT TYR-905.
RX   PubMed=20117004; DOI=10.1016/j.bmc.2010.01.011;
RA   Mologni L., Rostagno R., Brussolo S., Knowles P.P., Kjaer S.,
RA   Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N.Q.,
RA   Lucchini V., Gambacorti-Passerini C.;
RT   "Synthesis, structure-activity relationship and crystallographic studies of
RT   3-substituted indolin-2-one RET inhibitors.";
RL   Bioorg. Med. Chem. 18:1482-1496(2010).
RN   [41] {ECO:0007744|PDB:2X2U}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-270, GLYCOSYLATION AT ASN-151,
RP   AND DISULFIDE BOND.
RX   PubMed=20473317; DOI=10.1038/nsmb.1808;
RA   Kjaer S., Hanrahan S., Totty N., McDonald N.Q.;
RT   "Mammal-restricted elements predispose human RET to folding impairment by
RT   HSCR mutations.";
RL   Nat. Struct. Mol. Biol. 17:726-731(2010).
RN   [42]
RP   REVIEW ON HSCR VARIANTS.
RX   PubMed=9359036;
RA   Hofstra R.M.W., Osinga J., Buys C.H.C.M.;
RT   "Mutations in Hirschsprung disease: when does a mutation contribute to the
RT   phenotype.";
RL   Eur. J. Hum. Genet. 5:180-185(1997).
RN   [43]
RP   REVIEW ON VARIANTS.
RX   PubMed=9067749;
RX   DOI=10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m;
RA   Eng C., Mulligan L.M.;
RT   "Mutations of the RET proto-oncogene in the multiple endocrine neoplasia
RT   type 2 syndromes, related sporadic tumours, and Hirschsprung disease.";
RL   Hum. Mutat. 9:97-109(1997).
RN   [44]
RP   VARIANTS MEN2A/MTC TRP-611; SER-618; ARG-620; TYR-620 AND ARG-634.
RX   PubMed=8103403; DOI=10.1093/hmg/2.7.851;
RA   Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C.,
RA   Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.;
RT   "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.";
RL   Hum. Mol. Genet. 2:851-856(1993).
RN   [45]
RP   VARIANTS MEN2A GLY-618; 632-ASP--ARG-634; GLY-634; PHE-634; TYR-634 AND
RP   SER-634.
RX   PubMed=8099202; DOI=10.1038/363458a0;
RA   Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E.,
RA   Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H.,
RA   Tunnacliffe A., Ponder B.A.J.;
RT   "Germ-line mutations of the RET proto-oncogene in multiple endocrine
RT   neoplasia type 2A.";
RL   Nature 363:458-460(1993).
RN   [46]
RP   VARIANTS HSCR1 PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND
RP   LEU-973.
RX   PubMed=7704557; DOI=10.1159/000472371;
RA   Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I.,
RA   Pasini B., Tocco T., Lerone M., Cywes S., Moore S., Vanderwinden J.-M.,
RA   Abramowicz M.J., Kristoffersson U., Larsson L.T., Hamel B.C.J., Silengo M.,
RA   Martucciello G., Romeo G.;
RT   "Heterogeneity and low detection rate of RET mutations in Hirschsprung
RT   disease.";
RL   Eur. J. Hum. Genet. 2:272-280(1994).
RN   [47]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7911697; DOI=10.1093/hmg/3.2.237;
RA   Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S., Ponder M.A.,
RA   Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A., Ponder B.A.J.;
RT   "Point mutation within the tyrosine kinase domain of the RET proto-oncogene
RT   in multiple endocrine neoplasia type 2B and related sporadic tumours.";
RL   Hum. Mol. Genet. 3:237-241(1994).
RN   [48]
RP   VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634; GLY-634 AND
RP   TYR-634.
RX   PubMed=7915165; DOI=10.1093/hmg/3.4.635;
RA   Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N., Schuster M.K.,
RA   Browden D.W., Mao J.-I., Noll W.W.;
RT   "Germline RET mutations in MEN 2A and FMTC and their detection by simple
RT   DNA diagnostic tests.";
RL   Hum. Mol. Genet. 3:635-638(1994).
RN   [49]
RP   VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620.
RX   PubMed=7849720; DOI=10.1093/hmg/3.10.1895;
RA   Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B.,
RA   Hruban R.H., Sidransky D.;
RT   "RET proto-oncogene mutations in inherited and sporadic medullary thyroid
RT   cancer.";
RL   Hum. Mol. Genet. 3:1895-1897(1994).
RN   [50]
RP   VARIANTS MTC, AND VARIANTS MEN2A.
RX   PubMed=7874109; DOI=10.1093/hmg/3.11.1939;
RA   Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N.,
RA   Calmettes C., Modigliani E., Lenoir G.M.;
RT   "RET proto-oncogene mutations in French MEN 2A and FMTC families.";
RL   Hum. Mol. Genet. 3:1939-1943(1994).
RN   [51]
RP   VARIANTS HSCR1 TRP-609; ARG-618 AND ARG-620, VARIANT MEN2A ARG-618, AND
RP   VARIANT MTC ARG-620.
RX   PubMed=7881414; DOI=10.1093/hmg/3.12.2163;
RA   Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J.,
RA   Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A., Venter D.J.,
RA   Munnich A., Ponder B.A.J.;
RT   "Diverse phenotypes associated with exon 10 mutations of the RET proto-
RT   oncogene.";
RL   Hum. Mol. Genet. 3:2163-2167(1994).
RN   [52]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7906866; DOI=10.1038/367375a0;
RA   Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T.,
RA   Luo Y., Pasini B., Hoeppener J.W.M., Ploos van Amstel H.K., Romeo G.,
RA   Lips C.J.M., Buys C.H.C.M.;
RT   "A mutation in the RET proto-oncogene associated with multiple endocrine
RT   neoplasia type 2B and sporadic medullary thyroid carcinoma.";
RL   Nature 367:375-376(1994).
RN   [53]
RP   VARIANTS HSCR1 PRO-765; GLN-897 AND GLY-972.
RX   PubMed=8114938; DOI=10.1038/367377a0;
RA   Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I.,
RA   Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.;
RT   "Point mutations affecting the tyrosine kinase domain of the RET proto-
RT   oncogene in Hirschsprung's disease.";
RL   Nature 367:377-378(1994).
RN   [54]
RP   VARIANTS HSCR1 LEU-32; LEU-64; GLN-330 AND LEU-393.
RX   PubMed=8114939; DOI=10.1038/367378a0;
RA   Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S.,
RA   Nihoul-Fkete C., Ponder B.A.J., Munnich A.;
RT   "Mutations of the RET proto-oncogene in Hirschsprung's disease.";
RL   Nature 367:378-380(1994).
RN   [55]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7906417; DOI=10.1073/pnas.91.4.1579;
RA   Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E.,
RA   Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.;
RT   "Single missense mutation in the tyrosine kinase catalytic domain of the
RT   RET protooncogene is associated with multiple endocrine neoplasia type
RT   2B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994).
RN   [56]
RP   VARIANTS MTC; MEN2A AND MEN2B.
RX   PubMed=8625130;
RX   DOI=10.1002/1097-0142(19950801)76:3<479::aid-cncr2820760319>3.0.co;2-m;
RA   Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G.,
RA   Colomer A., Roth J., Heitz P.U.;
RT   "Analysis of RET protooncogene point mutations distinguishes heritable from
RT   nonheritable medullary thyroid carcinomas.";
RL   Cancer 76:479-489(1995).
RN   [57]
RP   VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634.
RX   PubMed=7860065; DOI=10.1007/bf00209399;
RA   Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S.,
RA   Takami H., Hikiji K., Nakamura Y.;
RT   "Germline mutations of the RET proto-oncogene in eight Japanese patients
RT   with multiple endocrine neoplasia type 2A (MEN2A).";
RL   Hum. Genet. 95:187-190(1995).
RN   [58]
RP   VARIANTS HSCR1 LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND VARIANT
RP   CYS-982.
RC   TISSUE=Blood;
RX   PubMed=7633441; DOI=10.1093/hmg/4.5.821;
RA   Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W.,
RA   Buys C.H.C.M., Cass D.T., Chakravarti A.;
RT   "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung
RT   disease.";
RL   Hum. Mol. Genet. 4:821-830(1995).
RN   [59]
RP   VARIANTS HSCR1.
RC   TISSUE=Leukocyte;
RX   PubMed=7581377; DOI=10.1093/hmg/4.8.1381;
RA   Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J., Boutrand L.,
RA   Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J., Lyonnet S.;
RT   "Diversity of RET proto-oncogene mutations in familial and sporadic
RT   Hirschsprung disease.";
RL   Hum. Mol. Genet. 4:1381-1386(1995).
RN   [60]
RP   VARIANT MEN2B THR-918, AND VARIANT TYR-922.
RX   PubMed=8595427; DOI=10.1093/hmg/4.10.1987;
RA   Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E., Goodfellow P.J.;
RT   "Two maternally derived missense mutations in the tyrosine kinase domain of
RT   the RET protooncogene in a patient with de novo MEN 2B.";
RL   Hum. Mol. Genet. 4:1987-1988(1995).
RN   [61]
RP   VARIANT MTC ASP-768.
RX   PubMed=7845675;
RA   Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J.,
RA   Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D., Ponder B.A.J.;
RT   "A novel point mutation in the tyrosine kinase domain of the RET proto-
RT   oncogene in sporadic medullary thyroid carcinoma and in a family with
RT   FMTC.";
RL   Oncogene 10:509-513(1995).
RN   [62]
RP   VARIANTS MTC ASP-768 AND LEU-804.
RX   PubMed=7784092;
RA   Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T.,
RA   Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J.,
RA   Lenoir G.M., Romeo G.;
RT   "RET mutations in exons 13 and 14 of FMTC patients.";
RL   Oncogene 10:2415-2419(1995).
RN   [63]
RP   VARIANTS HSCR1 TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND
RP   PRO-1061.
RA   Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C.,
RA   Buys C.H.C.M.;
RT   "Mutations in three genes are found associated with the development of
RT   Hirschsprung disease: RET, EDNRB and EDN3.";
RL   Am. J. Hum. Genet. 59:A263-A263(1996).
RN   [64]
RP   VARIANTS HSCR1 PRO-40 AND PRO-765.
RX   PubMed=9043870; DOI=10.1159/000472232;
RA   Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.;
RT   "Prevalence and parental origin of de novo RET mutations in Hirschsprung's
RT   disease.";
RL   Eur. J. Hum. Genet. 4:356-358(1996).
RN   [65]
RP   VARIANTS MTC/MEN2A.
RX   PubMed=8557249; DOI=10.1007/bf00218825;
RA   Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M., Lips C.J.M.,
RA   van Amstel H.K.P.;
RT   "Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A,
RT   MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.";
RL   Hum. Genet. 97:11-14(1996).
RN   [66]
RP   VARIANTS MEN2A, VARIANT MTC ASP-768, AND VARIANT MEN2B THR-918.
RX   PubMed=8807338;
RX   DOI=10.1002/(sici)1098-1004(1996)8:1<64::aid-humu9>3.0.co;2-p;
RA   Kambouris M., Jackson C.E., Feldman G.L.;
RT   "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial
RT   medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses
RT   of RET proto-oncogene mutations.";
RL   Hum. Mutat. 8:64-70(1996).
RN   [67]
RP   VARIANTS MEN2A.
RX   PubMed=8626834; DOI=10.1210/jcem.81.5.8626834;
RA   Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H., Haase R.,
RA   Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F., Ritter M.M.,
RA   Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U., Brabant G.,
RA   Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J., Doerr A.G.,
RA   Hoehne T., Hoernig-Franz I., Huefner M., Kress J., Langer H.J.,
RA   Lottermoser K., Schweikert H.U., Kusterer K., Menken U., Mercier J.,
RA   Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.;
RT   "Mutations of the ret protooncogene in German multiple endocrine neoplasia
RT   families: relation between genotype and phenotype.";
RL   J. Clin. Endocrinol. Metab. 81:1780-1783(1996).
RN   [68]
RP   VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS.
RX   PubMed=9097963; DOI=10.1093/hmg/6.4.587;
RA   Hoeppner W., Ritter M.M.;
RT   "A duplication of 12 bp in the critical cysteine rich domain of the RET
RT   proto-oncogene results in a distinct phenotype of multiple endocrine
RT   neoplasia type 2A.";
RL   Hum. Mol. Genet. 6:587-590(1997).
RN   [69]
RP   VARIANTS HSCR1 PRO-180; GLN-313; ARG-620 AND PHE-791.
RX   PubMed=9090527;
RX   DOI=10.1002/(sici)1098-1004(1997)9:3<243::aid-humu5>3.0.co;2-8;
RA   Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R., Pasini B.,
RA   Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T., Casasa J.M.,
RA   Cass D.T., Abramowicz M.J., Vanderwinden J.-M., Kravcenkiene I., Baric I.,
RA   Silengo M., Martucciello G., Romeo G.;
RT   "Frequency of RET mutations in long- and short-segment Hirschsprung
RT   disease.";
RL   Hum. Mutat. 9:243-249(1997).
RN   [70]
RP   VARIANT MTC ARG-618, AND VARIANT HSCR1 ARG-618.
RX   PubMed=9259198;
RX   DOI=10.1002/(sici)1098-1004(1997)10:2<155::aid-humu7>3.0.co;2-j;
RA   Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S.,
RA   Grynberg E., Yakobson E., Graff E., Lapidot M.;
RT   "Cys 618 Arg mutation in the RET proto-oncogene associated with familial
RT   medullary thyroid carcinoma and maternally transmitted Hirschsprung's
RT   disease suggesting a role for imprinting.";
RL   Hum. Mutat. 10:155-159(1997).
RN   [71]
RP   VARIANT MEN2B PHE-883.
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=9360560; DOI=10.1210/jcem.82.11.4508;
RA   Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M., Mulligan L.M.,
RA   Zajac J.D., Robinson B.G., Eng C.;
RT   "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in
RT   multiple endocrine neoplasia type 2B without codon 918 mutation.";
RL   J. Clin. Endocrinol. Metab. 82:3902-3904(1997).
RN   [72]
RP   VARIANT MTC ALA-891.
RX   PubMed=9398735; DOI=10.1210/jcem.82.12.4439;
RA   Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U.,
RA   Colantuoni V., Buys C.H.C.M.;
RT   "A novel point mutation in the intracellular domain of the ret
RT   protooncogene in a family with medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 82:4176-4178(1997).
RN   [73]
RP   VARIANTS HSCR1 SER-174 AND TYR-197.
RX   PubMed=9094028; DOI=10.1016/s0022-3468(97)90616-3;
RA   Kusafuka T., Wang Y., Puri P.;
RT   "Mutation analysis of the RET, the endothelin-B receptor, and the
RT   endothelin-3 genes in sporadic cases of Hirschsprung's disease.";
RL   J. Pediatr. Surg. 32:501-504(1997).
RN   [74]
RP   VARIANTS MTC; MEN2A AND MEN2B, AND VARIANT SER-691.
RX   PubMed=9223675; DOI=10.1038/sj.onc.1201102;
RA   Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K., Kitagawa W.,
RA   Akasu H., Takami H., Tanaka S., Wells S.A. Jr.;
RT   "Novel germline RET proto-oncogene mutations associated with medullary
RT   thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.";
RL   Oncogene 14:3103-3106(1997).
RN   [75]
RP   VARIANT MEN2B PHE-883.
RX   PubMed=9294615; DOI=10.1038/sj.onc.1201481;
RA   Smith D.P., Houghton C., Ponder B.A.J.;
RT   "Germline mutation of RET codon 883 in two cases of de novo MEN 2B.";
RL   Oncogene 15:1213-1217(1997).
RN   [76]
RP   VARIANT HSCR1 LEU-1039, AND VARIANT SER-691.
RX   PubMed=9497256; DOI=10.1086/301759;
RA   Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M.,
RA   Gaultier C., Munnich A., Lyonnet S.;
RT   "Mutations of the RET-GDNF signaling pathway in Ondine's curse.";
RL   Am. J. Hum. Genet. 62:715-717(1998).
RN   [77]
RP   VARIANT MTC GLY-611.
RX   PubMed=9677065;
RX   DOI=10.1002/(sici)1096-8628(19980707)78:3<271::aid-ajmg13>3.0.co;2-c;
RA   Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V., Rivera-Fillat F.;
RT   "Novel point mutation in exon 10 of the RET proto-oncogene in a family with
RT   medullary thyroid carcinoma.";
RL   Am. J. Med. Genet. 78:271-273(1998).
RN   [78]
RP   VARIANT CYS-982.
RX   PubMed=9760196; DOI=10.1007/s004390050797;
RA   Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.;
RT   "Phenotypic variation in a family with mutations in two Hirschsprung-
RT   related genes (RET and endothelin receptor B).";
RL   Hum. Genet. 103:145-148(1998).
RN   [79]
RP   VARIANTS MEN2A TYR-609; SER-618; ARG-620 AND TRP-620, AND VARIANTS HSCR1
RP   TYR-609; SER-618; ARG-620 AND TRP-620.
RX   PubMed=9384613; DOI=10.1093/hmg/7.1.129;
RA   Decker R.A., Peacock M.L., Watson P.;
RT   "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10
RT   genotypes and strong genotype-phenotype correlation.";
RL   Hum. Mol. Genet. 7:129-134(1998).
RN   [80]
RP   VARIANT MEN2A CYS-ARG-THR-636 INS.
RX   PubMed=9452064; DOI=10.1002/humu.1380110143;
RA   Hoeppner W., Dralle H., Brabant G.;
RT   "Duplication of 9 base pairs in the critical cysteine-rich domain of the
RT   RET proto-oncogene causes multiple endocrine neoplasia type 2A.";
RL   Hum. Mutat. Suppl. 1:S128-S130(1998).
RN   [81]
RP   VARIANT MTC MET-804.
RX   PubMed=9452077; DOI=10.1002/humu.1380110156;
RA   Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E.,
RA   Colantuoni V.;
RT   "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET
RT   proto-oncogene in two families affected by familial medullary thyroid
RT   carcinoma.";
RL   Hum. Mutat. Suppl. 1:S167-S171(1998).
RN   [82]
RP   VARIANTS MTC/MEN2A PHE-790 AND PHE-791.
RX   PubMed=9506724; DOI=10.1210/jcem.83.3.4619;
RA   Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M.,
RA   Raue F., Ritter M.M., Hoeppner W.;
RT   "A new hot spot for mutations in the ret protooncogene causing familial
RT   medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.";
RL   J. Clin. Endocrinol. Metab. 83:770-774(1998).
RN   [83]
RP   VARIANTS MTC AND MEN2A.
RX   PubMed=9621513; DOI=10.1007/s100380050048;
RA   Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A.,
RA   Nakamura Y.;
RT   "Mutational analysis of the RET proto-oncogene in 71 Japanese patients with
RT   medullary thyroid carcinoma.";
RL   J. Hum. Genet. 43:101-106(1998).
RN   [84]
RP   VARIANTS HSCR1 LYS-626 AND GLN-813.
RX   PubMed=10090908; DOI=10.1086/302329;
RA   Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A.,
RA   Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A.,
RA   Ceccherini I.;
RT   "Double heterozygosity for a RET substitution interfering with splicing and
RT   an EDNRB missense mutation in Hirschsprung disease.";
RL   Am. J. Hum. Genet. 64:1216-1221(1999).
RN   [85]
RP   VARIANTS HSCR1 ASN-1059 DEL AND PRO-1061.
RX   PubMed=10484767; DOI=10.1093/hmg/8.11.1989;
RA   Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S.,
RA   Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.;
RT   "Two distinct mutations of the RET receptor causing Hirschsprung's disease
RT   impair the binding of signalling effectors to a multifunctional docking
RT   site.";
RL   Hum. Mol. Genet. 8:1989-1999(1999).
RN   [86]
RP   VARIANT MTC GLU-GLU-CYS-531 INS.
RX   PubMed=10323403; DOI=10.1210/jcem.84.5.5665;
RA   Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P.,
RA   Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.;
RT   "A novel 9-base pair duplication in RET exon 8 in familial medullary
RT   thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:1700-1704(1999).
RN   [87]
RP   VARIANT MEN2A GLY-640.
RX   PubMed=10522989; DOI=10.1210/jcem.84.10.6056;
RA   Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D.,
RA   Bellastella A., Colantuoni V.;
RT   "A novel case of multiple endocrine neoplasia type 2A associated with two
RT   de novo mutations of the RET protooncogene.";
RL   J. Clin. Endocrinol. Metab. 84:3522-3527(1999).
RN   [88]
RP   VARIANTS MTC MET-804 AND LEU-844.
RX   PubMed=10826520; DOI=10.1055/s-2000-5806;
RA   Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.;
RT   "A RET double mutation in the germline of a kindred with FMTC.";
RL   Exp. Clin. Endocrinol. Diabetes 108:128-132(2000).
RN   [89]
RP   VARIANT GLN-600.
RX   PubMed=10612852;
RX   DOI=10.1002/(sici)1098-1004(200001)15:1<122::aid-humu41>3.0.co;2-7;
RA   Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G.,
RA   Borrego S.;
RT   "A new germline mutation, R600Q, within the coding region of RET proto-
RT   oncogene: a rare polymorphism or a MEN 2 causing mutation?";
RL   Hum. Mutat. 15:122-122(2000).
RN   [90]
RP   VARIANTS HSCR1 LEU-32; CYS-77; TRP-360 AND LYS-394.
RX   PubMed=10618407; DOI=10.1073/pnas.97.1.268;
RA   Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D.,
RA   Buys C.H.C.M., Lyonnet S., Chakravarti A.;
RT   "A human model for multigenic inheritance: phenotypic expression in
RT   Hirschsprung disease requires both the RET gene and a new 9q31 locus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000).
RN   [91]
RP   VARIANTS MTC GLY-639; GLY-641 AND PHE-922.
RX   PubMed=11692159; DOI=10.1007/s001090100250;
RA   Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N., Hosch S.B.,
RA   Garkavtseva R.F., Izbicki J.R.;
RT   "Three novel mutations in the RET proto-oncogene.";
RL   J. Mol. Med. 79:609-612(2001).
RN   [92]
RP   VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634;
RP   TRP-634 AND PHE-791.
RX   PubMed=12000816; DOI=10.1056/nejmoa020152;
RG   The Freiburg-Warsaw-Columbus pheochromocytoma study group;
RA   Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G.,
RA   Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A.,
RA   Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W., Treier M.,
RA   Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M., Klein-Franke A.,
RA   Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C.,
RA   Eng C.;
RT   "Germ-line mutations in nonsyndromic pheochromocytoma.";
RL   N. Engl. J. Med. 346:1459-1466(2002).
RN   [93]
RP   VARIANT HIS-114.
RX   PubMed=12086152; DOI=10.1620/tjem.196.241;
RA   Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K., Hashimoto M.,
RA   Hasegawa H., Shirasawa S., Hayasaka K.;
RT   "Congenital central hypoventilation syndrome: a novel mutation of the RET
RT   gene in an isolated case.";
RL   Tohoku J. Exp. Med. 196:241-246(2002).
RN   [94]
RP   VARIANTS HIS-67; HIS-114; GLU-432; ASN-489; SER-691 AND CYS-982.
RX   PubMed=14566559; DOI=10.1007/s00439-003-1036-z;
RA   Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H.,
RA   Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W.,
RA   Nakamura T., Hayasaka K.;
RT   "Molecular analysis of congenital central hypoventilation syndrome.";
RL   Hum. Genet. 114:22-26(2003).
RN   [95]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [96]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489;
RP   SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [97]
RP   VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; THR-918; LEU-1049 AND
RP   SER-1067, POSSIBLE INVOLVEMENT IN RENAL AGENESIS, AND CHARACTERIZATION OF
RP   VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; LEU-1049 AND
RP   SER-1067.
RX   PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008;
RA   Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E., Freemerman A.J.;
RT   "Renal aplasia in humans is associated with RET mutations.";
RL   Am. J. Hum. Genet. 82:344-351(2008).
RN   [98]
RP   VARIANTS HSCR1 549-LYS-GLY-550 DEL; CYS-114; GLY-145; LEU-155; PRO-175;
RP   ALA-278; PRO-278; ASN-300; GLN-313; ILE-316; LEU-339; TYR-353; GLN-360;
RP   MET-397; MET-412; ARG-423; LYS-480; GLN-595; LEU-679; GLN-694; SER-783;
RP   ARG-830; THR-907; LEU-961; VAL-1052; CYS-1062 AND THR-1064, AND VARIANTS
RP   HIS-114; ASN-278 AND MET-292.
RX   PubMed=22174939; DOI=10.1371/journal.pone.0028986;
RA   So M.T., Leon T.Y., Cheng G., Tang C.S., Miao X.P., Cornes B.K., Diem N.N.,
RA   Cui L., Ngan E.S., Lui V.C., Wu X.Z., Wang B., Wang H., Yuan Z.W.,
RA   Huang L.M., Li L., Xia H., Zhu D., Liu J., Nguyen T.L., Chan I.H.,
RA   Chung P.H., Liu X.L., Zhang R., Wong K.K., Sham P.C., Cherny S.S.,
RA   Tam P.K., Garcia-Barcelo M.M.;
RT   "RET mutational spectrum in Hirschsprung disease: evaluation of 601 Chinese
RT   patients.";
RL   PLoS ONE 6:E28986-E28986(2011).
CC   -!- FUNCTION: Receptor tyrosine-protein kinase involved in numerous
CC       cellular mechanisms including cell proliferation, neuronal navigation,
CC       cell migration, and cell differentiation upon binding with glial cell
CC       derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1.
CC       Regulates both cell death/survival balance and positional information.
CC       Required for the molecular mechanisms orchestration during intestine
CC       organogenesis; involved in the development of enteric nervous system
CC       and renal organogenesis during embryonic life, and promotes the
CC       formation of Peyer's patch-like structures, a major component of the
CC       gut-associated lymphoid tissue. Modulates cell adhesion via its
CC       cleavage by caspase in sympathetic neurons and mediates cell migration
CC       in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the
CC       development of the neural crest. Active in the absence of ligand,
CC       triggering apoptosis through a mechanism that requires receptor
CC       intracellular caspase cleavage. Acts as a dependence receptor; in the
CC       presence of the ligand GDNF in somatotrophs (within pituitary),
CC       promotes survival and down regulates growth hormone (GH) production,
CC       but triggers apoptosis in absence of GDNF. Regulates nociceptor
CC       survival and size. Triggers the differentiation of rapidly adapting
CC       (RA) mechanoreceptors. Mediator of several diseases such as
CC       neuroendocrine cancers; these diseases are characterized by aberrant
CC       integrins-regulated cell migration. Mediates, through interaction with
CC       GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem
CC       which induces inhibition of food-intake. Activates MAPK- and AKT-
CC       signaling pathways (PubMed:28846097, PubMed:28953886, PubMed:28846099).
CC       Isoform 1 in complex with GFRAL induces higher activation of MAPK-
CC       signaling pathway than isoform 2 in complex with GFRAL
CC       (PubMed:28846099). {ECO:0000269|PubMed:20064382,
CC       ECO:0000269|PubMed:20616503, ECO:0000269|PubMed:20702524,
CC       ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698,
CC       ECO:0000269|PubMed:28846097, ECO:0000269|PubMed:28846099,
CC       ECO:0000269|PubMed:28953886}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- ACTIVITY REGULATION: Repressed by 4-(3-hydroxyanilino)-quinolines
CC       derivatives, indolin-2-one-derivatives, 2-(alkylsulfanyl)-4-(3-thienyl)
CC       nicotinonitrile analogs, 3- and 4-substituted beta-carbolin-1-ones,
CC       vandetanib, motesanib, sorafenib (BAY 43-9006), cabozantinib (XL184),
CC       sunitinib, and withaferin A (WA). Inactivation by sorafenib both
CC       reduces kinase activity and promotes lysosomal degradation.
CC       {ECO:0000269|PubMed:17664273, ECO:0000269|PubMed:17884497,
CC       ECO:0000269|PubMed:19053769, ECO:0000269|PubMed:20117004,
CC       ECO:0000269|PubMed:20409618, ECO:0000269|PubMed:20605972,
CC       ECO:0000269|PubMed:21134556}.
CC   -!- SUBUNIT: Phosphorylated form interacts with the PBT domain of DOK2,
CC       DOK4 and DOK5 (By similarity). The phosphorylated form interacts with
CC       PLCG1 and GRB7 (By similarity). Interacts (not phosphorylated) with
CC       PTK2/FAK1 (via FERM domain) (PubMed:21454698). Extracellular cell-
CC       membrane anchored RET cadherin fragments form complex in neurons with
CC       reduced trophic status, preferentially at the contact sites between
CC       somas (PubMed:21357690). Interacts with AIP in the pituitary gland;
CC       this interaction prevents the formation of the AIP-survivin complex
CC       (PubMed:19366855). Binds to ARTN (By similarity). Interacts (inactive)
CC       with CBLC and CD2AP; dissociates upon activation by GDNF which
CC       increases CBLC:CD2AP interaction (PubMed:18753381). Interacts (via the
CC       extracellular domain) with GFRAL (via the extracellular domain); the
CC       interaction mediates cellular signaling upon interaction of GFRAL with
CC       its ligand GDF15 (PubMed:28953886, PubMed:28846097, PubMed:28846099).
CC       Interaction with GFRAL requires previous GDF15-binding to GFRAL
CC       (PubMed:28846097, PubMed:28846099). Interacts with GFRA1; in the
CC       presence of SORL1, the GFRA1/RET complex is targeted to endosomes
CC       (PubMed:23333276). Interacts with GDNF (PubMed:21994944).
CC       {ECO:0000250|UniProtKB:P35546, ECO:0000269|PubMed:18753381,
CC       ECO:0000269|PubMed:19366855, ECO:0000269|PubMed:21357690,
CC       ECO:0000269|PubMed:21454698, ECO:0000269|PubMed:21994944,
CC       ECO:0000269|PubMed:23333276, ECO:0000269|PubMed:28846097,
CC       ECO:0000269|PubMed:28846099, ECO:0000269|PubMed:28953886}.
CC   -!- INTERACTION:
CC       P07949; Q9UM73: ALK; NbExp=2; IntAct=EBI-2480756, EBI-357361;
CC       P07949; P22455: FGFR4; NbExp=2; IntAct=EBI-2480756, EBI-6256193;
CC       P07949; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-2480756, EBI-945833;
CC       P07949; P40763: STAT3; NbExp=3; IntAct=EBI-2480756, EBI-518675;
CC       P07949; Q62985: Sh2b1; Xeno; NbExp=3; IntAct=EBI-2480756, EBI-7395583;
CC       P07949-2; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-4423689, EBI-945833;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19823924,
CC       ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276,
CC       ECO:0000269|PubMed:28953886}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:19823924}. Endosome membrane
CC       {ECO:0000269|PubMed:19823924, ECO:0000269|PubMed:23333276}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:19823924}.
CC       Note=Predominantly located on the plasma membrane. In the presence of
CC       SORL1 and GFRA1, directed to endosomes. {ECO:0000269|PubMed:23333276}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=RET51;
CC         IsoId=P07949-1; Sequence=Displayed;
CC       Name=2; Synonyms=RET9;
CC         IsoId=P07949-2; Sequence=VSP_040735;
CC   -!- INDUCTION: Positively regulated by NKX2-1, PHOX2B, SOX10 and PAX3.
CC       {ECO:0000269|PubMed:19853745}.
CC   -!- PTM: Autophosphorylated on C-terminal tyrosine residues upon ligand
CC       stimulation. {ECO:0000269|PubMed:11061555, ECO:0000269|PubMed:14711813,
CC       ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004,
CC       ECO:0000269|PubMed:28846099}.
CC   -!- PTM: Proteolytically cleaved by caspase-3. The soluble RET kinase
CC       fragment is able to induce cell death. The extracellular cell-membrane
CC       anchored RET cadherin fragment accelerates cell adhesion in sympathetic
CC       neurons. {ECO:0000269|PubMed:21357690}.
CC   -!- POLYMORPHISM: The Cys-982 polymorphism may be associated with an
CC       increased risk for developing Hirschsprung disease.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of the
CC       large intestine (the colon) and the rectum. Genetic alterations are
CC       often associated with progression from premalignant lesion (adenoma) to
CC       invasive adenocarcinoma. Risk factors for cancer of the colon and
CC       rectum include colon polyps, long-standing ulcerative colitis, and
CC       genetic family history. Note=The disease may be caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hirschsprung disease 1 (HSCR1) [MIM:142623]: A disorder of
CC       neural crest development characterized by absence of enteric ganglia
CC       along a variable length of the intestine. It is the most common cause
CC       of congenital intestinal obstruction. Early symptoms range from
CC       complete acute neonatal obstruction, characterized by vomiting,
CC       abdominal distention and failure to pass stool, to chronic constipation
CC       in the older child. {ECO:0000269|PubMed:10090908,
CC       ECO:0000269|PubMed:10484767, ECO:0000269|PubMed:10618407,
CC       ECO:0000269|PubMed:22174939, ECO:0000269|PubMed:7581377,
CC       ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:7704557,
CC       ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:8114938,
CC       ECO:0000269|PubMed:8114939, ECO:0000269|PubMed:9043870,
CC       ECO:0000269|PubMed:9090527, ECO:0000269|PubMed:9094028,
CC       ECO:0000269|PubMed:9259198, ECO:0000269|PubMed:9384613,
CC       ECO:0000269|PubMed:9497256, ECO:0000269|Ref.63}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Medullary thyroid carcinoma (MTC) [MIM:155240]: Rare tumor
CC       derived from the C cells of the thyroid. Three hereditary forms are
CC       known, that are transmitted in an autosomal dominant fashion: (a)
CC       multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB
CC       (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of
CC       MTC cases and where MTC is the only clinical manifestation.
CC       {ECO:0000269|PubMed:10323403, ECO:0000269|PubMed:10826520,
CC       ECO:0000269|PubMed:11692159, ECO:0000269|PubMed:7784092,
CC       ECO:0000269|PubMed:7845675, ECO:0000269|PubMed:7849720,
CC       ECO:0000269|PubMed:7874109, ECO:0000269|PubMed:7881414,
CC       ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8103403,
CC       ECO:0000269|PubMed:8557249, ECO:0000269|PubMed:8625130,
CC       ECO:0000269|PubMed:8807338, ECO:0000269|PubMed:9223675,
CC       ECO:0000269|PubMed:9259198, ECO:0000269|PubMed:9398735,
CC       ECO:0000269|PubMed:9452077, ECO:0000269|PubMed:9506724,
CC       ECO:0000269|PubMed:9621513, ECO:0000269|PubMed:9677065}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Multiple neoplasia 2B (MEN2B) [MIM:162300]: Uncommon inherited
CC       cancer syndrome characterized by predisposition to MTC and
CC       phaeochromocytoma which is associated with marfanoid habitus, mucosal
CC       neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of
CC       the intestine tract. Then the disease progresses rapidly with the
CC       development of metastatic MTC and a pheochromocytome in 50% of cases.
CC       {ECO:0000269|PubMed:7906417, ECO:0000269|PubMed:7906866,
CC       ECO:0000269|PubMed:7911697, ECO:0000269|PubMed:8595427,
CC       ECO:0000269|PubMed:8807338, ECO:0000269|PubMed:9294615,
CC       ECO:0000269|PubMed:9360560}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing
CC       tumor of chromaffin tissue of the adrenal medulla or sympathetic
CC       paraganglia. The cardinal symptom, reflecting the increased secretion
CC       of epinephrine and norepinephrine, is hypertension, which may be
CC       persistent or intermittent. {ECO:0000269|PubMed:12000816}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Multiple neoplasia 2A (MEN2A) [MIM:171400]: The most frequent
CC       form of medullary thyroid cancer (MTC). It is an inherited cancer
CC       syndrome characterized by MTC, phaeochromocytoma and/or
CC       hyperparathyroidism. {ECO:0000269|PubMed:10522989,
CC       ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7874109,
CC       ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165,
CC       ECO:0000269|PubMed:8099202, ECO:0000269|PubMed:8103403,
CC       ECO:0000269|PubMed:8626834, ECO:0000269|PubMed:8807338,
CC       ECO:0000269|PubMed:9097963, ECO:0000269|PubMed:9384613,
CC       ECO:0000269|PubMed:9452064}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Various chromosomal aberrations involving RET are known.
CC       Some of them have been found in papillary thyroid carcinomas (PTCs)
CC       (PubMed:12787916, PubMed:2406025, PubMed:10980597, PubMed:10439047).
CC       Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene
CC       (PubMed:2406025). Inversion inv(10)(q11.2;q11.2) generates the
CC       RET/NCOA4 (PTC3) oncogene. Translocation t(10;14)(q11;q32) with GOLGA5
CC       generates the RET/GOLGA5 (PTC5) oncogene (PubMed:2734021).
CC       Translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET
CC       fusion (PubMed:10980597). Translocation t(6;10)(p21.3;q11.2) with
CC       TRIM27/RFP generates the Delta RFP/RET oncogene (PubMed:12787916).
CC       Translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET
CC       (PTC7) oncogene (PubMed:10439047). Translocation t(7;10)(q32;q11) with
CC       TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene (PubMed:10439047).
CC       Translocation t(6;10)(p21.3;q11.2) with TRIM27/RFP generates the
CC       TRIM27/RET oncogene (PubMed:3037315). {ECO:0000269|PubMed:10439047,
CC       ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:12787916,
CC       ECO:0000269|PubMed:2406025, ECO:0000269|PubMed:2734021,
CC       ECO:0000269|PubMed:3037315}.
CC   -!- DISEASE: Note=Mutations in RET have been detected in patients with
CC       renal agenesis suggesting a possible involvement of this gene in
CC       disease pathogenesis.
CC   -!- MISCELLANEOUS: Treatment with withaferin A (WA) leads tumor regression
CC       in medullary thyroid carcinomas (MTC).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: Original thought to be dephosphorylated by PTPRJ on Tyr-905,
CC       Tyr-1015 and Tyr-1062. However this paper was retracted due to
CC       manipulation of immunoblot data. {ECO:0000305|PubMed:16778204,
CC       ECO:0000305|PubMed:30552125}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36524.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAA36786.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA33787.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAC14882.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RETID76.html";
CC   -!- WEB RESOURCE: Name=MEN2 RET database;
CC       URL="http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK291807; BAF84496.1; -; mRNA.
DR   EMBL; AC010864; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC004257; AAH04257.1; -; mRNA.
DR   EMBL; X15262; CAA33333.1; -; mRNA.
DR   EMBL; X12949; CAA31408.1; -; mRNA.
DR   EMBL; M16029; AAA36786.1; ALT_INIT; mRNA.
DR   EMBL; X15786; CAA33787.1; ALT_INIT; mRNA.
DR   EMBL; M31213; AAA36524.1; ALT_INIT; mRNA.
DR   EMBL; AJ297349; CAC14882.1; ALT_INIT; mRNA.
DR   CCDS; CCDS53525.1; -. [P07949-2]
DR   CCDS; CCDS7200.1; -. [P07949-1]
DR   PIR; A27203; TVHURE.
DR   PIR; A34630; A34630.
DR   PIR; B34735; B34735.
DR   PIR; S05582; S05582.
DR   RefSeq; NP_065681.1; NM_020630.4. [P07949-2]
DR   RefSeq; NP_066124.1; NM_020975.4. [P07949-1]
DR   PDB; 2IVS; X-ray; 2.00 A; A/B=705-1013.
DR   PDB; 2IVT; X-ray; 2.60 A; A=705-1013.
DR   PDB; 2IVU; X-ray; 2.50 A; A=705-1013.
DR   PDB; 2IVV; X-ray; 2.25 A; A=705-1013.
DR   PDB; 2X2K; X-ray; 2.60 A; A=705-1013.
DR   PDB; 2X2L; X-ray; 2.00 A; A=705-1013.
DR   PDB; 2X2M; X-ray; 2.50 A; A/B=705-1013.
DR   PDB; 2X2U; X-ray; 2.00 A; A=29-270.
DR   PDB; 4CKI; X-ray; 2.12 A; A=705-1013.
DR   PDB; 4CKJ; X-ray; 1.65 A; A=705-1013.
DR   PDB; 4UX8; EM; 24.00 A; A/B=29-635.
DR   PDB; 5AMN; X-ray; 2.57 A; A=705-1012.
DR   PDB; 5FM2; X-ray; 3.30 A; A=659-1013.
DR   PDB; 5FM3; X-ray; 2.95 A; A=659-1013.
DR   PDB; 6FEK; X-ray; 2.30 A; A=705-1013.
DR   PDB; 6GL7; EM; 6.30 A; E/F=29-635.
DR   PDB; 6I82; X-ray; 2.05 A; A/B=705-1013.
DR   PDB; 6I83; X-ray; 1.88 A; A=705-1013.
DR   PDB; 6NE7; X-ray; 1.99 A; A=705-1013.
DR   PDB; 6NEC; X-ray; 1.87 A; A/C=705-1013.
DR   PDB; 6NJA; X-ray; 1.92 A; A=705-1013.
DR   PDB; 6Q2J; EM; 4.10 A; E/F=29-635.
DR   PDB; 6Q2N; EM; 4.40 A; E/F=29-635.
DR   PDB; 6Q2O; EM; 3.65 A; E/F=29-635.
DR   PDB; 6Q2R; EM; 4.30 A; E/F/Y/Z=29-635.
DR   PDB; 6Q2S; EM; 3.80 A; E/F=29-635.
DR   PDB; 6VHG; X-ray; 2.30 A; A=705-1013.
DR   PDB; 7DU8; X-ray; 2.75 A; A/B=705-1013.
DR   PDB; 7DU9; X-ray; 2.31 A; A/B=705-1013.
DR   PDB; 7DUA; X-ray; 1.64 A; A/B=705-1013.
DR   PDB; 7JU5; X-ray; 1.90 A; A/B=705-1013.
DR   PDB; 7JU6; X-ray; 2.06 A; A/B=705-1013.
DR   PDB; 7NZN; X-ray; 2.39 A; A=705-1013.
DR   PDB; 7RUN; X-ray; 3.51 A; A/B=705-1013.
DR   PDBsum; 2IVS; -.
DR   PDBsum; 2IVT; -.
DR   PDBsum; 2IVU; -.
DR   PDBsum; 2IVV; -.
DR   PDBsum; 2X2K; -.
DR   PDBsum; 2X2L; -.
DR   PDBsum; 2X2M; -.
DR   PDBsum; 2X2U; -.
DR   PDBsum; 4CKI; -.
DR   PDBsum; 4CKJ; -.
DR   PDBsum; 4UX8; -.
DR   PDBsum; 5AMN; -.
DR   PDBsum; 5FM2; -.
DR   PDBsum; 5FM3; -.
DR   PDBsum; 6FEK; -.
DR   PDBsum; 6GL7; -.
DR   PDBsum; 6I82; -.
DR   PDBsum; 6I83; -.
DR   PDBsum; 6NE7; -.
DR   PDBsum; 6NEC; -.
DR   PDBsum; 6NJA; -.
DR   PDBsum; 6Q2J; -.
DR   PDBsum; 6Q2N; -.
DR   PDBsum; 6Q2O; -.
DR   PDBsum; 6Q2R; -.
DR   PDBsum; 6Q2S; -.
DR   PDBsum; 6VHG; -.
DR   PDBsum; 7DU8; -.
DR   PDBsum; 7DU9; -.
DR   PDBsum; 7DUA; -.
DR   PDBsum; 7JU5; -.
DR   PDBsum; 7JU6; -.
DR   PDBsum; 7NZN; -.
DR   PDBsum; 7RUN; -.
DR   AlphaFoldDB; P07949; -.
DR   SMR; P07949; -.
DR   BioGRID; 111911; 141.
DR   CORUM; P07949; -.
DR   DIP; DIP-41449N; -.
DR   IntAct; P07949; 205.
DR   MINT; P07949; -.
DR   STRING; 9606.ENSP00000347942; -.
DR   BindingDB; P07949; -.
DR   ChEMBL; CHEMBL2041; -.
DR   DrugBank; DB01809; 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine.
DR   DrugBank; DB12742; Amuvatinib.
DR   DrugBank; DB08875; Cabozantinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB15822; Pralsetinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB15685; Selpercatinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB05294; Vandetanib.
DR   DrugCentral; P07949; -.
DR   GuidetoPHARMACOLOGY; 2185; -.
DR   GlyGen; P07949; 13 sites.
DR   iPTMnet; P07949; -.
DR   PhosphoSitePlus; P07949; -.
DR   BioMuta; RET; -.
DR   DMDM; 547807; -.
DR   EPD; P07949; -.
DR   jPOST; P07949; -.
DR   MassIVE; P07949; -.
DR   MaxQB; P07949; -.
DR   PaxDb; P07949; -.
DR   PeptideAtlas; P07949; -.
DR   PRIDE; P07949; -.
DR   ProteomicsDB; 52047; -. [P07949-1]
DR   ProteomicsDB; 52048; -. [P07949-2]
DR   TopDownProteomics; P07949-2; -. [P07949-2]
DR   Antibodypedia; 1904; 1243 antibodies from 40 providers.
DR   DNASU; 5979; -.
DR   Ensembl; ENST00000340058.6; ENSP00000344798.4; ENSG00000165731.21. [P07949-2]
DR   Ensembl; ENST00000355710.8; ENSP00000347942.3; ENSG00000165731.21. [P07949-1]
DR   GeneID; 5979; -.
DR   KEGG; hsa:5979; -.
DR   MANE-Select; ENST00000355710.8; ENSP00000347942.3; NM_020975.6; NP_066124.1.
DR   UCSC; uc001jak.2; human. [P07949-1]
DR   CTD; 5979; -.
DR   DisGeNET; 5979; -.
DR   GeneCards; RET; -.
DR   GeneReviews; RET; -.
DR   HGNC; HGNC:9967; RET.
DR   HPA; ENSG00000165731; Group enriched (adrenal gland, brain, parathyroid gland).
DR   MalaCards; RET; -.
DR   MIM; 114500; phenotype.
DR   MIM; 142623; phenotype.
DR   MIM; 155240; phenotype.
DR   MIM; 162300; phenotype.
DR   MIM; 164761; gene.
DR   MIM; 171300; phenotype.
DR   MIM; 171400; phenotype.
DR   neXtProt; NX_P07949; -.
DR   OpenTargets; ENSG00000165731; -.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   Orphanet; 99361; Familial medullary thyroid carcinoma.
DR   Orphanet; 99803; Haddad syndrome.
DR   Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma.
DR   Orphanet; 388; Hirschsprung disease.
DR   Orphanet; 247698; Multiple endocrine neoplasia type 2A.
DR   Orphanet; 247709; Multiple endocrine neoplasia type 2B.
DR   Orphanet; 1848; Renal agenesis, bilateral.
DR   Orphanet; 93100; Renal agenesis, unilateral.
DR   Orphanet; 357191; Selection of therapeutic option in non-small cell lung carcinoma.
DR   Orphanet; 276621; Sporadic pheochromocytoma/secreting paraganglioma.
DR   PharmGKB; PA34335; -.
DR   VEuPathDB; HostDB:ENSG00000165731; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000158499; -.
DR   HOGENOM; CLU_009530_0_0_1; -.
DR   InParanoid; P07949; -.
DR   OMA; FHLGQHL; -.
DR   OrthoDB; 507784at2759; -.
DR   PhylomeDB; P07949; -.
DR   TreeFam; TF317640; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P07949; -.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   SignaLink; P07949; -.
DR   SIGNOR; P07949; -.
DR   BioGRID-ORCS; 5979; 17 hits in 1108 CRISPR screens.
DR   ChiTaRS; RET; human.
DR   EvolutionaryTrace; P07949; -.
DR   GeneWiki; RET_proto-oncogene; -.
DR   GenomeRNAi; 5979; -.
DR   Pharos; P07949; Tclin.
DR   PRO; PR:P07949; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P07949; protein.
DR   Bgee; ENSG00000165731; Expressed in substantia nigra pars reticulata and 129 other tissues.
DR   ExpressionAtlas; P07949; baseline and differential.
DR   Genevisible; P07949; HS.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; IEA:Ensembl.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098797; C:plasma membrane protein complex; IDA:CAFA.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IDA:FlyBase.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl.
DR   GO; GO:0048484; P:enteric nervous system development; IEA:Ensembl.
DR   GO; GO:0035860; P:glial cell-derived neurotrophic factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro.
DR   GO; GO:0060384; P:innervation; IEA:Ensembl.
DR   GO; GO:0097021; P:lymphocyte migration into lymphoid organs; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; IEA:Ensembl.
DR   GO; GO:0033619; P:membrane protein proteolysis; IDA:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl.
DR   GO; GO:0007158; P:neuron cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0042551; P:neuron maturation; IEA:Ensembl.
DR   GO; GO:0061146; P:Peyer's patch morphogenesis; ISS:UniProtKB.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0072300; P:positive regulation of metanephric glomerulus development; ISS:UniProtKB.
DR   GO; GO:0014042; P:positive regulation of neuron maturation; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0033141; P:positive regulation of peptidyl-serine phosphorylation of STAT protein; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0007497; P:posterior midgut development; TAS:ProtInc.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0030155; P:regulation of cell adhesion; IDA:UniProtKB.
DR   GO; GO:0048265; P:response to pain; ISS:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0035799; P:ureter maturation; IEA:Ensembl.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   InterPro; IPR002126; Cadherin-like_dom.
DR   InterPro; IPR015919; Cadherin-like_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR041163; Ret_CLD1.
DR   InterPro; IPR040667; Ret_CLD3.
DR   InterPro; IPR041317; RET_CLD4.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016249; Tyr_kinase_Ret_rcpt.
DR   Pfam; PF00028; Cadherin; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF17756; RET_CLD1; 1.
DR   Pfam; PF17812; RET_CLD3; 1.
DR   Pfam; PF17813; RET_CLD4; 1.
DR   PIRSF; PIRSF000631; TyrPK_receptor_Ret; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49313; SSF49313; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50268; CADHERIN_2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell membrane; Chromosomal rearrangement; Disease variant; Disulfide bond;
KW   Endosome; Glycoprotein; Hirschsprung disease; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL          1..28
FT                   /evidence="ECO:0000255"
FT   CHAIN           29..1114
FT                   /note="Proto-oncogene tyrosine-protein kinase receptor Ret"
FT                   /id="PRO_0000024450"
FT   CHAIN           29..707
FT                   /note="Extracellular cell-membrane anchored RET cadherin
FT                   120 kDa fragment"
FT                   /id="PRO_0000415292"
FT   CHAIN           708..1017
FT                   /note="Soluble RET kinase fragment"
FT                   /id="PRO_0000415293"
FT   TOPO_DOM        29..635
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        636..657
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        658..1114
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          168..272
FT                   /note="Cadherin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00043"
FT   DOMAIN          724..1016
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        874
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         730..738
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         758
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         805..807
FT                   /ligand="semaxanib"
FT                   /ligand_id="ChEBI:CHEBI:91083"
FT                   /ligand_note="inhibitor"
FT                   /evidence="ECO:0000269|PubMed:20117004,
FT                   ECO:0007744|PDB:2X2M"
FT   SITE            587..588
FT                   /note="Breakpoint for translocation to form the TRIM27/RET
FT                   oncogene"
FT   SITE            707..708
FT                   /note="Cleavage; by caspase-3"
FT   SITE            712..713
FT                   /note="Breakpoint for translocation to form PCM1-RET; RET-
FT                   CCDC6; RET-GOLGA5; RET-TRIM24 and RET-TRIM33 oncogenes"
FT   SITE            1017..1018
FT                   /note="Cleavage; by caspase-3"
FT   MOD_RES         696
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         806
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14711813"
FT   MOD_RES         809
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14711813"
FT   MOD_RES         900
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14711813,
FT                   ECO:0000269|PubMed:16928683"
FT   MOD_RES         905
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14711813,
FT                   ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004,
FT                   ECO:0000269|PubMed:28846099"
FT   MOD_RES         981
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14711813"
FT   MOD_RES         1015
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11061555"
FT   MOD_RES         1062
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11061555,
FT                   ECO:0000269|PubMed:14711813, ECO:0000269|PubMed:28846099"
FT   MOD_RES         1090
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14711813"
FT   MOD_RES         1096
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14711813"
FT   CARBOHYD        98
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        151
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:20473317"
FT   CARBOHYD        199
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        336
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        343
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        361
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        367
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        377
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        394
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        448
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        468
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        554
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        137..142
FT                   /evidence="ECO:0000269|PubMed:20473317"
FT   VAR_SEQ         1064..1114
FT                   /note="MSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS
FT                   -> RISHAFTRF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3037315"
FT                   /id="VSP_040735"
FT   VARIANT         20
FT                   /note="P -> L (in HSCR1; sporadic form)"
FT                   /evidence="ECO:0000269|PubMed:7633441"
FT                   /id="VAR_009459"
FT   VARIANT         32
FT                   /note="S -> L (in HSCR1; familial form; dbSNP:rs76764689)"
FT                   /evidence="ECO:0000269|PubMed:10618407,
FT                   ECO:0000269|PubMed:8114939"
FT                   /id="VAR_006295"
FT   VARIANT         40
FT                   /note="L -> P (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:7704557,
FT                   ECO:0000269|PubMed:9043870"
FT                   /id="VAR_009492"
FT   VARIANT         64
FT                   /note="P -> L (in HSCR1; familial form; dbSNP:rs77596424)"
FT                   /evidence="ECO:0000269|PubMed:8114939"
FT                   /id="VAR_006296"
FT   VARIANT         67
FT                   /note="R -> H (in dbSNP:rs192489011)"
FT                   /evidence="ECO:0000269|PubMed:14566559"
FT                   /id="VAR_018153"
FT   VARIANT         77
FT                   /note="R -> C (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:10618407"
FT                   /id="VAR_009460"
FT   VARIANT         93
FT                   /note="G -> S (in HSCR1; unknown pathological significance;
FT                   dbSNP:rs1477699803)"
FT                   /evidence="ECO:0000269|PubMed:7633441"
FT                   /id="VAR_006297"
FT   VARIANT         114
FT                   /note="R -> C (in HSCR1; unknown pathological significance;
FT                   dbSNP:rs747483905)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067101"
FT   VARIANT         114
FT                   /note="R -> H (in dbSNP:rs76397662)"
FT                   /evidence="ECO:0000269|PubMed:12086152,
FT                   ECO:0000269|PubMed:14566559, ECO:0000269|PubMed:22174939"
FT                   /id="VAR_018154"
FT   VARIANT         142
FT                   /note="C -> S (in HSCR1; sporadic form)"
FT                   /id="VAR_006298"
FT   VARIANT         145
FT                   /note="V -> G (in HSCR1; also in a colorectal cancer
FT                   sample; somatic mutation; dbSNP:rs1588863999)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:22174939"
FT                   /id="VAR_035711"
FT   VARIANT         155
FT                   /note="P -> L (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067102"
FT   VARIANT         157
FT                   /note="C -> Y (in HSCR1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|Ref.63"
FT                   /id="VAR_009461"
FT   VARIANT         163
FT                   /note="R -> Q (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs149403911)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041762"
FT   VARIANT         174
FT                   /note="F -> S (in HSCR1; sporadic form)"
FT                   /evidence="ECO:0000269|PubMed:9094028"
FT                   /id="VAR_009462"
FT   VARIANT         175
FT                   /note="R -> P (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067103"
FT   VARIANT         180
FT                   /note="R -> P (in HSCR1; sporadic form)"
FT                   /evidence="ECO:0000269|PubMed:9090527"
FT                   /id="VAR_009463"
FT   VARIANT         197
FT                   /note="C -> Y (in HSCR1; sporadic form)"
FT                   /evidence="ECO:0000269|PubMed:9094028"
FT                   /id="VAR_009464"
FT   VARIANT         198
FT                   /note="P -> T (in a patient with renal agenesis; unknown
FT                   pathological significance; prevents phosphorylation in
FT                   response to GDNF; dbSNP:rs76736111)"
FT                   /evidence="ECO:0000269|PubMed:18252215"
FT                   /id="VAR_044392"
FT   VARIANT         231
FT                   /note="R -> H (in HSCR1; familial form; dbSNP:rs79661516)"
FT                   /id="VAR_006299"
FT   VARIANT         251
FT                   /note="E -> K (in HSCR1; familial form; dbSNP:rs562449603)"
FT                   /id="VAR_006300"
FT   VARIANT         278
FT                   /note="T -> A (in HSCR1; dbSNP:rs541929171)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067104"
FT   VARIANT         278
FT                   /note="T -> N (found in two patients with Hirschsprung
FT                   disease; dbSNP:rs35118262)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:22174939"
FT                   /id="VAR_041763"
FT   VARIANT         278
FT                   /note="T -> P (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067105"
FT   VARIANT         287
FT                   /note="R -> Q (in HSCR1; sporadic form;
FT                   dbSNP:rs1564491460)"
FT                   /id="VAR_006301"
FT   VARIANT         292
FT                   /note="V -> M (found in patients with Hirschsprung disease;
FT                   unknown pathological significance; dbSNP:rs34682185)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:22174939"
FT                   /id="VAR_041764"
FT   VARIANT         300
FT                   /note="D -> N (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067106"
FT   VARIANT         313
FT                   /note="R -> Q (in HSCR1; dbSNP:rs77702891)"
FT                   /evidence="ECO:0000269|PubMed:22174939,
FT                   ECO:0000269|PubMed:9090527"
FT                   /id="VAR_009465"
FT   VARIANT         316
FT                   /note="S -> I (in HSCR1; dbSNP:rs1060499894)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067107"
FT   VARIANT         330
FT                   /note="R -> Q (in HSCR1; dbSNP:rs80236571)"
FT                   /evidence="ECO:0000269|PubMed:7633441,
FT                   ECO:0000269|PubMed:8114939"
FT                   /id="VAR_006302"
FT   VARIANT         339
FT                   /note="S -> L (in HSCR1; dbSNP:rs774829203)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067108"
FT   VARIANT         353
FT                   /note="D -> Y (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067109"
FT   VARIANT         359
FT                   /note="N -> K (in HSCR1; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|Ref.63"
FT                   /id="VAR_009466"
FT   VARIANT         360
FT                   /note="R -> Q (in HSCR1; dbSNP:rs762472027)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067110"
FT   VARIANT         360
FT                   /note="R -> W (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:10618407,
FT                   ECO:0000269|PubMed:16959974"
FT                   /id="VAR_009467"
FT   VARIANT         376
FT                   /note="V -> A (in a patient with renal agenesis; unknown
FT                   pathological significance; constitutively phosphorylated;
FT                   expressed only the immature intracellular form)"
FT                   /evidence="ECO:0000269|PubMed:18252215"
FT                   /id="VAR_044393"
FT   VARIANT         393
FT                   /note="F -> L (in HSCR1; familial form; dbSNP:rs78098482)"
FT                   /evidence="ECO:0000269|PubMed:8114939"
FT                   /id="VAR_006303"
FT   VARIANT         394
FT                   /note="N -> H (in a patient with renal agenesis; unknown
FT                   pathological significance; prevents phosphorylation in
FT                   response to GDNF)"
FT                   /evidence="ECO:0000269|PubMed:18252215"
FT                   /id="VAR_044394"
FT   VARIANT         394
FT                   /note="N -> K (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:10618407"
FT                   /id="VAR_009468"
FT   VARIANT         397
FT                   /note="V -> M (in HSCR1; dbSNP:rs183729115)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067111"
FT   VARIANT         399
FT                   /note="P -> L (in HSCR1; sporadic form;
FT                   dbSNP:rs1554818362)"
FT                   /evidence="ECO:0000269|PubMed:7704557"
FT                   /id="VAR_006304"
FT   VARIANT         412
FT                   /note="V -> M (in HSCR1; dbSNP:rs746970700)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067112"
FT   VARIANT         423
FT                   /note="G -> R (in HSCR1; dbSNP:rs767601598)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067113"
FT   VARIANT         432
FT                   /note="A -> E (found in a patient with congenital central
FT                   hypoventilation syndrome; unknown pathological
FT                   significance; dbSNP:rs552057730)"
FT                   /evidence="ECO:0000269|PubMed:14566559"
FT                   /id="VAR_018155"
FT   VARIANT         475
FT                   /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs138624658)"
FT                   /id="VAR_006305"
FT   VARIANT         480
FT                   /note="E -> K (in HSCR1; dbSNP:rs537874538)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067114"
FT   VARIANT         489
FT                   /note="D -> N (in dbSNP:rs9282834)"
FT                   /evidence="ECO:0000269|PubMed:14566559,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_018156"
FT   VARIANT         531
FT                   /note="C -> CEEC (in MTC; familial form)"
FT                   /evidence="ECO:0000269|PubMed:10323403"
FT                   /id="VAR_009469"
FT   VARIANT         549..550
FT                   /note="Missing (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067115"
FT   VARIANT         593
FT                   /note="G -> E (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035712"
FT   VARIANT         595
FT                   /note="E -> Q (in HSCR1; dbSNP:rs1483605155)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067116"
FT   VARIANT         600
FT                   /note="R -> Q (in dbSNP:rs377767393)"
FT                   /evidence="ECO:0000269|PubMed:10612852"
FT                   /id="VAR_008966"
FT   VARIANT         609
FT                   /note="C -> G (in MEN2A; dbSNP:rs77558292)"
FT                   /id="VAR_009470"
FT   VARIANT         609
FT                   /note="C -> R (in MEN2A; dbSNP:rs77558292)"
FT                   /id="VAR_009471"
FT   VARIANT         609
FT                   /note="C -> W (in HSCR1; familial form; dbSNP:rs377767396)"
FT                   /evidence="ECO:0000269|PubMed:7881414"
FT                   /id="VAR_006307"
FT   VARIANT         609
FT                   /note="C -> Y (in MTC, MEN2A and HSCR1; familial and
FT                   sporadic forms; dbSNP:rs77939446)"
FT                   /evidence="ECO:0000269|PubMed:7633441,
FT                   ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:9384613,
FT                   ECO:0000269|Ref.63"
FT                   /id="VAR_006306"
FT   VARIANT         611
FT                   /note="C -> G (in MTC; familial form; dbSNP:rs377767391)"
FT                   /evidence="ECO:0000269|PubMed:9677065"
FT                   /id="VAR_009472"
FT   VARIANT         611
FT                   /note="C -> R (in MEN2A; dbSNP:rs377767391)"
FT                   /id="VAR_009473"
FT   VARIANT         611
FT                   /note="C -> S (in MEN2A; dbSNP:rs377767391)"
FT                   /id="VAR_009474"
FT   VARIANT         611
FT                   /note="C -> W (in MEN2A and MTC; familial form;
FT                   dbSNP:rs80069458)"
FT                   /evidence="ECO:0000269|PubMed:8103403"
FT                   /id="VAR_006308"
FT   VARIANT         611
FT                   /note="C -> Y (in MEN2A; dbSNP:rs377767397)"
FT                   /id="VAR_006309"
FT   VARIANT         618
FT                   /note="C -> F (in MEN2A and MTC; familial form;
FT                   dbSNP:rs79781594)"
FT                   /id="VAR_006312"
FT   VARIANT         618
FT                   /note="C -> G (in MEN2A; dbSNP:rs76262710)"
FT                   /evidence="ECO:0000269|PubMed:8099202"
FT                   /id="VAR_006310"
FT   VARIANT         618
FT                   /note="C -> R (in MEN2A, MTC and HSCR1; dbSNP:rs76262710)"
FT                   /evidence="ECO:0000269|PubMed:7849720,
FT                   ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165,
FT                   ECO:0000269|PubMed:9259198"
FT                   /id="VAR_006311"
FT   VARIANT         618
FT                   /note="C -> S (in MEN2A, HSCR1 and MTC; familial and
FT                   sporadic forms; dbSNP:rs79781594)"
FT                   /evidence="ECO:0000269|PubMed:7849720,
FT                   ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165,
FT                   ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9384613"
FT                   /id="VAR_006313"
FT   VARIANT         618
FT                   /note="C -> Y (in MEN2A and MTC; familial form;
FT                   dbSNP:rs79781594)"
FT                   /id="VAR_006314"
FT   VARIANT         620
FT                   /note="C -> F (in MEN2A and MTC; familial form;
FT                   dbSNP:rs77503355)"
FT                   /evidence="ECO:0000269|PubMed:7915165"
FT                   /id="VAR_006318"
FT   VARIANT         620
FT                   /note="C -> G (in MEN2A and MTC; familial and sporadic
FT                   forms; dbSNP:rs77316810)"
FT                   /id="VAR_006315"
FT   VARIANT         620
FT                   /note="C -> R (in MEN2A, MTC and HSCR1; familial and
FT                   sporadic forms; dbSNP:rs77316810)"
FT                   /evidence="ECO:0000269|PubMed:7633441,
FT                   ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165,
FT                   ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9090527,
FT                   ECO:0000269|PubMed:9384613, ECO:0000269|Ref.63"
FT                   /id="VAR_006316"
FT   VARIANT         620
FT                   /note="C -> S (in MEN2A and MTC; familial form;
FT                   dbSNP:rs77503355)"
FT                   /evidence="ECO:0000269|PubMed:7849720,
FT                   ECO:0000269|PubMed:7860065"
FT                   /id="VAR_006317"
FT   VARIANT         620
FT                   /note="C -> W (in MEN2A and HSCR1; dbSNP:rs79890926)"
FT                   /evidence="ECO:0000269|PubMed:9384613"
FT                   /id="VAR_009475"
FT   VARIANT         620
FT                   /note="C -> Y (in MEN2A; dbSNP:rs77503355)"
FT                   /evidence="ECO:0000269|PubMed:8103403"
FT                   /id="VAR_006319"
FT   VARIANT         626
FT                   /note="Q -> K (in HSCR1; sporadic form;
FT                   dbSNP:rs1255575160)"
FT                   /evidence="ECO:0000269|PubMed:10090908"
FT                   /id="VAR_009476"
FT   VARIANT         630
FT                   /note="C -> F (in MEN2A and MTC; familial form;
FT                   dbSNP:rs377767405)"
FT                   /id="VAR_006320"
FT   VARIANT         630
FT                   /note="C -> S (in MTC; sporadic form; dbSNP:rs377767405)"
FT                   /id="VAR_009477"
FT   VARIANT         630
FT                   /note="C -> Y (in MTC; familial and sporadic forms;
FT                   dbSNP:rs377767405)"
FT                   /id="VAR_009478"
FT   VARIANT         631
FT                   /note="D -> G (in thyroid carcinoma; somatic mutation;
FT                   dbSNP:rs121913308)"
FT                   /id="VAR_006321"
FT   VARIANT         632..634
FT                   /note="ELC -> DVR (in MEN2A; dbSNP:rs377767408)"
FT                   /id="VAR_006322"
FT   VARIANT         634..635
FT                   /note="CR -> WG (in MEN2A)"
FT                   /id="VAR_006329"
FT   VARIANT         634
FT                   /note="C -> CHELC (in MEN2A)"
FT                   /evidence="ECO:0000269|PubMed:9097963"
FT                   /id="VAR_009479"
FT   VARIANT         634
FT                   /note="C -> F (in MEN2A and pheochromocytoma;
FT                   dbSNP:rs75996173)"
FT                   /evidence="ECO:0000269|PubMed:12000816,
FT                   ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202"
FT                   /id="VAR_006324"
FT   VARIANT         634
FT                   /note="C -> G (in MEN2A and pheochromocytoma;
FT                   dbSNP:rs75076352)"
FT                   /evidence="ECO:0000269|PubMed:12000816,
FT                   ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202"
FT                   /id="VAR_006323"
FT   VARIANT         634
FT                   /note="C -> R (in MEN2A, pheochromocytoma and MTC; familial
FT                   form; also found as somatic mutation in a sporadic thyroid
FT                   carcinoma; dbSNP:rs75076352)"
FT                   /evidence="ECO:0000269|PubMed:12000816,
FT                   ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:8103403"
FT                   /id="VAR_006326"
FT   VARIANT         634
FT                   /note="C -> S (in MEN2A, pheochromocytoma and MTC; familial
FT                   form; dbSNP:rs75076352)"
FT                   /evidence="ECO:0000269|PubMed:12000816,
FT                   ECO:0000269|PubMed:8099202"
FT                   /id="VAR_006327"
FT   VARIANT         634
FT                   /note="C -> W (in MEN2A, pheochromocytoma and MTC; familial
FT                   form; dbSNP:rs77709286)"
FT                   /evidence="ECO:0000269|PubMed:12000816"
FT                   /id="VAR_006328"
FT   VARIANT         634
FT                   /note="C -> Y (in MEN2A, pheochromocytoma and MTC; familial
FT                   form; dbSNP:rs75996173)"
FT                   /evidence="ECO:0000269|PubMed:12000816,
FT                   ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165,
FT                   ECO:0000269|PubMed:8099202"
FT                   /id="VAR_006325"
FT   VARIANT         636
FT                   /note="T -> TCRT (in MEN2A)"
FT                   /evidence="ECO:0000269|PubMed:9452064"
FT                   /id="VAR_006330"
FT   VARIANT         639
FT                   /note="A -> G (in MTC; sporadic form)"
FT                   /evidence="ECO:0000269|PubMed:11692159"
FT                   /id="VAR_012743"
FT   VARIANT         640
FT                   /note="A -> G (in MEN2A; dbSNP:rs78935588)"
FT                   /evidence="ECO:0000269|PubMed:10522989"
FT                   /id="VAR_009480"
FT   VARIANT         641
FT                   /note="A -> G (in MTC; sporadic form)"
FT                   /evidence="ECO:0000269|PubMed:11692159"
FT                   /id="VAR_012744"
FT   VARIANT         679
FT                   /note="P -> L (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067117"
FT   VARIANT         690
FT                   /note="S -> P (in HSCR1; sporadic form)"
FT                   /id="VAR_006331"
FT   VARIANT         691
FT                   /note="G -> S (in dbSNP:rs1799939)"
FT                   /evidence="ECO:0000269|PubMed:14566559,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9223675,
FT                   ECO:0000269|PubMed:9497256"
FT                   /id="VAR_006332"
FT   VARIANT         694
FT                   /note="R -> Q (in HSCR1; dbSNP:rs141185224)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067118"
FT   VARIANT         749
FT                   /note="R -> T (in dbSNP:rs34288963)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041765"
FT   VARIANT         762
FT                   /note="E -> Q (in HSCR1; sporadic form)"
FT                   /evidence="ECO:0000269|PubMed:7704557"
FT                   /id="VAR_009481"
FT   VARIANT         765
FT                   /note="S -> P (in HSCR1; dbSNP:rs75075748)"
FT                   /evidence="ECO:0000269|PubMed:7704557,
FT                   ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:9043870"
FT                   /id="VAR_009493"
FT   VARIANT         767
FT                   /note="S -> R (in HSCR1; sporadic form)"
FT                   /id="VAR_006334"
FT   VARIANT         768
FT                   /note="E -> D (in MTC; familial and sporadic forms;
FT                   dbSNP:rs78014899)"
FT                   /evidence="ECO:0000269|PubMed:7784092,
FT                   ECO:0000269|PubMed:7845675, ECO:0000269|PubMed:8807338"
FT                   /id="VAR_006335"
FT   VARIANT         778
FT                   /note="V -> I (in a patient with renal agenesis; unknown
FT                   pathological significance; constitutively phosphorylated;
FT                   dbSNP:rs75686697)"
FT                   /evidence="ECO:0000269|PubMed:18252215"
FT                   /id="VAR_044395"
FT   VARIANT         783
FT                   /note="N -> S (in HSCR1; dbSNP:rs587778656)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067119"
FT   VARIANT         790
FT                   /note="L -> F (in MEN2A and MTC; familial form;
FT                   dbSNP:rs75030001)"
FT                   /evidence="ECO:0000269|PubMed:9506724"
FT                   /id="VAR_009482"
FT   VARIANT         791
FT                   /note="Y -> F (in HSCR1, pheochromocytoma, MTC and MEN2A;
FT                   familial form; dbSNP:rs77724903)"
FT                   /evidence="ECO:0000269|PubMed:12000816,
FT                   ECO:0000269|PubMed:9090527, ECO:0000269|PubMed:9506724"
FT                   /id="VAR_009483"
FT   VARIANT         804
FT                   /note="V -> L (in MTC; familial form; dbSNP:rs79658334)"
FT                   /evidence="ECO:0000269|PubMed:7784092"
FT                   /id="VAR_006336"
FT   VARIANT         804
FT                   /note="V -> M (in MTC; familial form; dbSNP:rs79658334)"
FT                   /evidence="ECO:0000269|PubMed:10826520,
FT                   ECO:0000269|PubMed:9452077"
FT                   /id="VAR_006337"
FT   VARIANT         813
FT                   /note="R -> Q (in HSCR1; sporadic form;
FT                   dbSNP:rs1318733775)"
FT                   /evidence="ECO:0000269|PubMed:10090908"
FT                   /id="VAR_009484"
FT   VARIANT         826
FT                   /note="Y -> S (in dbSNP:rs34617196)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041766"
FT   VARIANT         830
FT                   /note="G -> R (in HSCR1; dbSNP:rs200127630)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067120"
FT   VARIANT         844
FT                   /note="R -> L (in MTC; familial form; dbSNP:rs55947360)"
FT                   /evidence="ECO:0000269|PubMed:10826520,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_011582"
FT   VARIANT         873
FT                   /note="R -> Q (in HSCR1; sporadic form;
FT                   dbSNP:rs1451004715)"
FT                   /id="VAR_006338"
FT   VARIANT         883
FT                   /note="A -> F (in MEN2B; somatic mutation in sporadic
FT                   medullary thyroid carcinoma; requires 2 nucleotide
FT                   substitutions; dbSNP:rs377767429)"
FT                   /evidence="ECO:0000269|PubMed:9294615,
FT                   ECO:0000269|PubMed:9360560"
FT                   /id="VAR_009485"
FT   VARIANT         891
FT                   /note="S -> A (in MTC; familial form; dbSNP:rs75234356)"
FT                   /evidence="ECO:0000269|PubMed:9398735"
FT                   /id="VAR_009486"
FT   VARIANT         893
FT                   /note="F -> L (in HSCR1; sporadic form)"
FT                   /id="VAR_006339"
FT   VARIANT         894
FT                   /note="G -> S (in a patient with renal agenesis; unknown
FT                   pathological significance; constitutively phosphorylated;
FT                   expressed only the immature intracellular form)"
FT                   /evidence="ECO:0000269|PubMed:18252215"
FT                   /id="VAR_044396"
FT   VARIANT         897
FT                   /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs76087194)"
FT                   /evidence="ECO:0000269|PubMed:7704557,
FT                   ECO:0000269|PubMed:8114938"
FT                   /id="VAR_006340"
FT   VARIANT         907
FT                   /note="K -> E (in HSCR1; sporadic form; dbSNP:rs377767430)"
FT                   /id="VAR_006341"
FT   VARIANT         907
FT                   /note="K -> T (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067121"
FT   VARIANT         918
FT                   /note="M -> T (in MEN2B and MTC; sporadic form; somatic
FT                   mutation; also found in a patient with renal agenesis;
FT                   dbSNP:rs74799832)"
FT                   /evidence="ECO:0000269|PubMed:18252215,
FT                   ECO:0000269|PubMed:7906417, ECO:0000269|PubMed:7906866,
FT                   ECO:0000269|PubMed:7911697, ECO:0000269|PubMed:8595427,
FT                   ECO:0000269|PubMed:8807338"
FT                   /id="VAR_006342"
FT   VARIANT         921
FT                   /note="E -> K (in HSCR1; sporadic form)"
FT                   /id="VAR_006343"
FT   VARIANT         922
FT                   /note="S -> F (in MTC; sporadic form; dbSNP:rs377767432)"
FT                   /evidence="ECO:0000269|PubMed:11692159"
FT                   /id="VAR_012745"
FT   VARIANT         922
FT                   /note="S -> Y (in dbSNP:rs377767432)"
FT                   /evidence="ECO:0000269|PubMed:8595427"
FT                   /id="VAR_009487"
FT   VARIANT         946
FT                   /note="T -> M (in MEN2B and MTC; familial form)"
FT                   /id="VAR_006345"
FT   VARIANT         961
FT                   /note="F -> L (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067122"
FT   VARIANT         972
FT                   /note="R -> G (in HSCR1; familial form; dbSNP:rs76534745)"
FT                   /evidence="ECO:0000269|PubMed:7704557,
FT                   ECO:0000269|PubMed:8114938"
FT                   /id="VAR_006346"
FT   VARIANT         973
FT                   /note="P -> L (in HSCR1; familial form)"
FT                   /evidence="ECO:0000269|PubMed:7704557"
FT                   /id="VAR_006347"
FT   VARIANT         980
FT                   /note="M -> T (in HSCR1; sporadic form)"
FT                   /id="VAR_006348"
FT   VARIANT         982
FT                   /note="R -> C (in dbSNP:rs17158558)"
FT                   /evidence="ECO:0000269|PubMed:14566559,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:9760196"
FT                   /id="VAR_006349"
FT   VARIANT         1039
FT                   /note="P -> L (in HSCR1; dbSNP:rs79853121)"
FT                   /evidence="ECO:0000269|PubMed:9497256"
FT                   /id="VAR_018157"
FT   VARIANT         1039
FT                   /note="P -> Q (in dbSNP:rs79853121)"
FT                   /id="VAR_009488"
FT   VARIANT         1049
FT                   /note="P -> L (in a patient with renal agenesis; unknown
FT                   pathological significance; prevents phosphorylation in
FT                   response to GDNF; dbSNP:rs1490712863)"
FT                   /evidence="ECO:0000269|PubMed:18252215"
FT                   /id="VAR_044397"
FT   VARIANT         1052
FT                   /note="L -> V (in HSCR1; dbSNP:rs1564501947)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067123"
FT   VARIANT         1059
FT                   /note="Missing (in HSCR1)"
FT                   /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.63"
FT                   /id="VAR_009489"
FT   VARIANT         1061
FT                   /note="L -> P (in HSCR1; dbSNP:rs536486113)"
FT                   /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.63"
FT                   /id="VAR_009490"
FT   VARIANT         1062
FT                   /note="Y -> C (in HSCR1; dbSNP:rs587778659)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_067124"
FT   VARIANT         1064
FT                   /note="M -> T (in HSCR1; familial form; dbSNP:rs149513065)"
FT                   /evidence="ECO:0000269|PubMed:22174939"
FT                   /id="VAR_009491"
FT   VARIANT         1067
FT                   /note="P -> S (in a patient with renal agenesis; unknown
FT                   pathological significance; prevents phosphorylation in
FT                   response to GDNF; dbSNP:rs775583354)"
FT                   /evidence="ECO:0000269|PubMed:18252215"
FT                   /id="VAR_044398"
FT   VARIANT         1112
FT                   /note="F -> Y (in a bladder transitional cell carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041767"
FT   MUTAGEN         707
FT                   /note="D->N: Impaired cleavage by caspase-3 and loss of
FT                   induced cell death."
FT                   /evidence="ECO:0000269|PubMed:21357690"
FT   MUTAGEN         708..1114
FT                   /note="Missing: Loss of induced cell death, but increased
FT                   cell aggregation."
FT                   /evidence="ECO:0000269|PubMed:21357690"
FT   MUTAGEN         758
FT                   /note="K->R: Loss of kinase activity. No effect on
FT                   interaction with and dissociation from CBLC and CD2AP."
FT                   /evidence="ECO:0000269|PubMed:18753381,
FT                   ECO:0000269|PubMed:21357690"
FT   MUTAGEN         1062
FT                   /note="Y->F: Abolishes GFRAL-mediated MAPK1/MAPK2
FT                   phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:28953886"
FT   CONFLICT        647
FT                   /note="I -> V (in Ref. 6; AAA36786)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        664
FT                   /note="A -> S (in Ref. 1; BAF84496)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        750
FT                   /note="A -> G (in Ref. 9; AAA36524)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        904
FT                   /note="S -> P (in Ref. 6; AAA36786)"
FT                   /evidence="ECO:0000305"
FT   STRAND          30..32
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          34..41
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          49..52
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          70..73
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   HELIX           75..77
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          79..82
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          85..88
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   TURN            90..92
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          94..99
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   HELIX           103..111
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          120..126
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   TURN            139..141
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          142..152
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   HELIX           157..159
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   HELIX           162..166
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          174..178
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          184..187
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   HELIX           191..196
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          202..208
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          212..215
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          222..227
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   TURN            231..233
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          235..245
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   STRAND          252..263
FT                   /evidence="ECO:0007829|PDB:2X2U"
FT   HELIX           705..710
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   TURN            715..717
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           721..723
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          724..733
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          736..744
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           746..748
FT                   /evidence="ECO:0007829|PDB:6NEC"
FT   STRAND          751..759
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           766..781
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          790..794
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          796..798
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          801..805
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           812..819
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          822..826
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          844..846
FT                   /evidence="ECO:0007829|PDB:6NJA"
FT   HELIX           848..867
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           877..879
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          880..883
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           884..886
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   STRAND          887..890
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           893..895
FT                   /evidence="ECO:0007829|PDB:7JU5"
FT   TURN            900..902
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           915..917
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           920..925
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           930..945
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           957..959
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           960..965
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           978..987
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           992..994
FT                   /evidence="ECO:0007829|PDB:7DUA"
FT   HELIX           998..1010
FT                   /evidence="ECO:0007829|PDB:7DUA"
SQ   SEQUENCE   1114 AA;  124319 MW;  A3DA0CE01A19A441 CRC64;
     MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP
     EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT
     VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR
     PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV
     AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD
     ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR
     NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA
     QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE
     LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR
     CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR
     GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY
     HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP
     RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK
     QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH
     PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY
     EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL
     FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA
     STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGMSDPNWP GESPVPLTRA
     DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS
//
